Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC )-Reference-Cited by-同舟云学术

Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC )

Published:2020-05-07 Issue:9 Volume:147 Page:2493-2502
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lorenzen Sylvie¹^ORCID,Knorrenschild Jorge Riera²,Pauligk Claudia³⁴,Hegewisch‐Becker Susanna⁵,Seraphin Jörg⁶,Thuss‐Patience Peter⁷,Kopp Hans‐Georg⁸,Dechow Tobias⁹,Vogel Arndt¹⁰,Luley Kim Barbara¹¹,Pink Daniel¹²,Stahl Michael¹³,Kullmann Frank¹⁴,Hebart Holger¹⁵,Siveke Jens¹⁶¹⁷^ORCID,Egger Matthias¹⁸,Homann Nils¹⁹,Probst Stephan²⁰,Goetze Thorsten Oliver³⁴,Al‐Batran Salah‐Eddin³⁴

Affiliation:

1. Third Department of Internal Medicine (Hematology/Medical Oncology) Klinikum Rechts der Isar, Technische Universität München Munich Germany

2. Department of Hematology and Oncology Universitätsklinikum Giessen und Marburg Marburg Germany

3. Krankenhaus Nordwest, University Cancer Center Frankfurt Germany

4. Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Frankfurt Germany

5. HOPE‐Hämatologisch‐Onkologische Praxis Eppendorf Hamburg Germany

6. Helios MVZ Südniedersachsen GmbH Northeim Germany

7. Department of Hematology, Oncology and Tumor Immunology Charite‐University Medicine Berlin Berlin Germany

8. University Hospital, Medical Center II Tuebingen Germany

9. Onkologie Ravensburg Ravensburg Germany

10. Hannover Medical School Hannover Germany

11. UKSH Campus Luebeck Lübeck Germany

12. Helios Klinikum Bad Saarow, Department of Internal Medicine‐ Hematology, Oncology and Stem Cell Transplantation, Greifswald University Hospital Greifswald Germany

13. Department of Medical Oncology Evang. Kliniken Essen‐Mitte gGmbH Essen Germany

14. First Department of Medicine Nordoberpfalz Hospital Weiden Germany

15. Stauferklinikum Mutlangen Germany

16. Second Department of Internal Medicine Technical University Munich Germany

17. Institute for Developmental Cancer Therapeutics, West German Cancer Center University Hospital Essen Essen Germany

18. Ortenau ‐ Clinic Lahr Medical Clinic Lahr Germany

19. Department of Internal Medicine II Academic Teaching Hospital Wolfsburg Wolfsburg Germany

20. Klinikum Bielefeld Bielefeld Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33025

Reference29 articles.

1. Cancer statistics, 2000

2. HowlanderN NooneAM;KrapchoM et al. SEER Cancer Statistics Review 1975–2008.http://seercancergov/csr/1975_2008.2008.

3. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

4. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

5. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy;Cancer Treatment Reviews;2023-11

2. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study;Gastric Cancer;2023-10-31

3. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415);BMC Cancer;2023-06-19

4. DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells;Experimental Cell Research;2023-06

5. Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis;Journal of Gastrointestinal Cancer;2023-05-23